Skip to Content
Merck
  • Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations.

Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations.

NPJ vaccines (2019-12-31)
N C Salisch, A Izquierdo Gil, D N Czapska-Casey, L Vorthoren, J Serroyen, J Tolboom, E Saeland, H Schuitemaker, R C Zahn
ABSTRACT

Respiratory Syncytial Virus (RSV) can cause severe respiratory disease, yet a licensed vaccine is not available. We determined the immunogenicity of two homologous and one heterologous intramuscular prime-boost vaccination regimens using replication-incompetent adenoviral vectors of human serotype 26 and 35 (Ad26 and Ad35), expressing a prototype antigen based on the wild-type fusion (F) protein of RSV strain A2 in adult, RSV-naive cynomolgus macaques. All regimens induced substantial, boostable antibody responses that recognized the F protein in pre- and postfusion conformation, neutralized multiple strains of RSV, and persisted for at least 80 weeks. Vaccination induced durable systemic RSV-F-specific T-cell responses characterized mainly by CD4+ T cells expressing Th1-type cytokines, as well as RSV-F-specific CD4+ and CD8+ T cells, IgG, and IgA in the respiratory tract. Intramuscular immunization with Ad26 and 35 vectors thus is a promising approach for the development of an optimized RSV vaccine expected to induce long-lasting humoral and cellular immune responses that distribute systemically and to mucosal sites.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-RSV Antibody, fusion protein, all type A, B strains, clone 133-1H, clone 133-1H, Chemicon®, from mouse
Pricing and availability is not currently available.